Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE).
Mod RheumatolAug 31, 2026
Clinical ResearchRheumatology
Yoshiya Tanaka, Hisanori Umehara, Hirokazu Sato et al.
✦ AI-curated · Sources linked
In 30 seconds
This subgroup analysis of the MITIGATE study evaluated the efficacy and safety of inebilizumab in 27 Japanese patients with IgG4-related disease. The randomized, double-blind, placebo-controlled trial found that inebilizumab significantly reduced the annualized flare rate and glucocorticoid use, with no treatment-related flares in the treatment group compared to 57.1% in the placebo group.
Key findings
- Inebilizumab reduced the annualized flare rate compared to placebo.
- 57.1% of patients in the placebo group experienced flares.
- No treatment-related flares were observed in the inebilizumab group.
- Inebilizumab lowered glucocorticoid use in treated patients.
Why it matters
The findings suggest that inebilizumab may provide effective management of IgG4-related disease in Japanese patients, potentially reducing reliance on glucocorticoids and improving patient outcomes.